Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537056 · ClinicalTrials.gov registry record · NA
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT00537056: Completed NA study, sponsored by Stanford University.
NCT00537056 is a NA study that has completed, run by Stanford University. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00537056, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).
Interventions
- DRUG Sunitinib
- PROCEDURE FDG PET CT
- PROCEDURE DCE MRI
- DRUG F-18 Fluoro-deoxi-glucose
- DRUG Gadolinium-DTPA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00537056
The ClinicalTrials.gov registry entry for NCT00537056 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sunitinib is the first listed.
NCT00537056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00537056 about?
NCT00537056 is a clinical study titled "Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI". To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).
What is the current status of trial NCT00537056?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2007-10. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00537056?
The interventions under investigation include: Sunitinib (DRUG), FDG PET CT (PROCEDURE), DCE MRI (PROCEDURE), F-18 Fluoro-deoxi-glucose (DRUG), Gadolinium-DTPA (DRUG).
Who is sponsoring clinical trial NCT00537056?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.